Insights

Why uniQure’s Stock Price Jumped Today

What happened

After gene-therapy specialist uniQure (NASDAQ: QURE) reported positive interim results from a phase 1/2 clinical trial early Thursday, its stock surged, gaining 18.5% as of 10:54 a.m. ET. That gene therapy, AMT-130, is intended to treat Huntington’s disease, and per the latest update, it appears to have an acceptable side effect profile when used at a low dose. Even 12 months after treatment, there weren’t any serious adverse events linked to it among the six patients receiving the treatment in the low-dose cohort of the study.

The company also reported some early evidence suggesting that the medicine could be effective at reducing the levels of certain disease-linked biomarkers. The report did not address whether patients in the trials actually experienced fewer symptoms as of yet.

So what

AMT-130 is uniQure’s most mature wholly-owned pipeline program, though it does have another treatment in phase 3 trials that it’s pursuing with the help of a research and development collaborator. So Thursday’s update means that the biotech is one step closer to generating revenue from sales and becoming profitable without outside help. 

But it’s important to remember that the road to commercializing AMT-130 is still quite long, and a lot could go wrong along the way. 

Now what

In the second half of this year, uniQure will seek to finalize enrollment of an open-label trial for AMT-130 in the European Union. Then, in Q2 2023, it’ll analyze a full two years of follow-up safety and efficacy data for the low-dose cohort, and take a look at the first year of data for the high-dose cohort. 

All eyes will be on the efficacy data from the low dose wing in any future data updates, as it will shed light on AMT-130’s promise as a functional cure for Huntington’s disease.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex Securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here To Get Started
FREE AAPL, TSLA, AMZN, PFE or MRO Share(s)
REGISTER TO BE ELIGIBLE FOR FREE SHARES
TRAVEL ACROSS THE FINANCIAL WORLD
Act Fast - Promotion Ends In
Click Here For More Info